233 related articles for article (PubMed ID: 25798061)
21. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
[TBL] [Abstract][Full Text] [Related]
22. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
[TBL] [Abstract][Full Text] [Related]
23. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
25. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
26. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
[TBL] [Abstract][Full Text] [Related]
27. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
28. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract][Full Text] [Related]
29. Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer.
Affolter A; Muller MF; Sommer K; Stenzinger A; Zaoui K; Lorenz K; Wolf T; Sharma S; Wolf J; Perner S; Weber KJ; Freier K; Plinkert PK; Hess J; Weichert W
Head Neck; 2016 Apr; 38 Suppl 1():E2049-61. PubMed ID: 26918677
[TBL] [Abstract][Full Text] [Related]
30. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
[TBL] [Abstract][Full Text] [Related]
32. The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1.
Lee DS; Lee S; Kim C; Kim D; Kim KP; Yoo C
Anticancer Res; 2022 Jul; 42(7):3435-3443. PubMed ID: 35790285
[TBL] [Abstract][Full Text] [Related]
33. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
Williams TM; Flecha AR; Keller P; Ram A; Karnak D; Galbán S; Galbán CJ; Ross BD; Lawrence TS; Rehemtulla A; Sebolt-Leopold J
Mol Cancer Ther; 2012 May; 11(5):1193-202. PubMed ID: 22411900
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
Jung M; Park KH; Kim HM; Kim TS; Zhang X; Park SM; Beom SH; Kim HS; Cheong JH; Chung HC; Soong J; Lin SC; Rha SY
Gastric Cancer; 2019 Nov; 22(6):1153-1163. PubMed ID: 31098863
[TBL] [Abstract][Full Text] [Related]
35. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
36. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Bliesath J; Huser N; Omori M; Bunag D; Proffitt C; Streiner N; Ho C; Siddiqui-Jain A; O'Brien SE; Lim JK; Ryckman DM; Anderes K; Rice WG; Drygin D
Cancer Lett; 2012 Sep; 322(1):113-8. PubMed ID: 22387988
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.
Yu M; Yeh J; Van Waes C
Cancer Res; 2006 Jul; 66(13):6722-31. PubMed ID: 16818647
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
40.
Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]